13th week of 2014 patent applcation highlights part 53 |
Patent application number | Title | Published |
20140088015 | Mucin 3 EGF-like Domains - The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGF like domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or nucleic acids. | 2014-03-27 |
20140088016 | MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT - The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders. | 2014-03-27 |
20140088017 | USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME - The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers. | 2014-03-27 |
20140088018 | COMPOSITIONS AND METHODS FOR TREATMENT OF GYNECOLOGIC CANCERS - Molecules and compositions that can be used in the treatment of gynecologic cancers are described. ApoA-1, in particular, is demonstrated to inhibit the proliferation of cancer cells reduce tumor size in a mouse model of ovarian cancer. | 2014-03-27 |
20140088019 | Monovalent and Multivalent Multispecific Complexes and Uses Thereof - Monovalent and multivalent multispecific complexes including ELP-MRD fusion proteins containing one or more modular recognition domains (MRDs) that bind target antigens are described. The use of these monovalent and multivalent multispecific complexes (e.g., ELP-MRD fusion proteins) in diagnostic, prognostic, and therapeutic applications and methods of making these complexes are also described. | 2014-03-27 |
20140088020 | Composition and Methods for Treatment of Cancer - The present invention contemplates therapeutic constructs comprising wild type SEG superantigen, its homologues and tumor targeting fusion proteins devoid of neutralizing antibodies in human sera for treatment of cancer | 2014-03-27 |
20140088021 | Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds - Compounds comprising a binding moiety, water-soluble, non-peptidic polymer, and drug are provided. Also provided are methods preparing such compounds, compositions comprising such compounds and methods for administering and using such compounds and compositions. | 2014-03-27 |
20140088022 | Novel Solid Materials of and Methods for Obtaining Them - The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals. | 2014-03-27 |
20140088023 | sGCalpha1 Inhibiting Compositions, and Methods of Treatment of Cancers Therewith - The present invention provides materials and methods useful to treat various sGCα1-expressing cancers. Materials include peptides which interfere with sGCα1's pro-survival functions, thereby resulting in apoptosis of sGCα1-expressing cells. In addition, the present invention provides screening assays, diagnostic assays, methods to prognose, methods to treat, and kits. | 2014-03-27 |
20140088024 | Vesiculins - The inventions relate generally to vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof, related compositions and formulations and their preparation and use, nucleic acids encoding such vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof and related vectors and host cells, hybridomas and antibodies, and methods for the prevention and treatment of conditions, diseases and disorders that would be improved, eased, or lessened by the administration of a composition of the invention, including but not limited to glucose metabolism diseases. | 2014-03-27 |
20140088025 | LYOPHILIZATION OF SYNTHETIC LIPOSOMAL PULMONARY SURFACTANT - Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. A method of making lyophilized pulmonary surfactants is described. | 2014-03-27 |
20140088026 | LYOPHILIZATION OF SYNTHETIC LIPOSOMAL PULMONARY SURFACTANT - Lyophilized pulmonary surfactants having an increased specific surface area and porosity are described. Methods of making the lyophilized pulmonary surfactants are also described. | 2014-03-27 |
20140088027 | PHARMACEUTICAL COMPOSITION COMPRISING AN SGLT2 INHIBITOR AND A PPAR- GAMMA AGONIST AND USES THEREOF - The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor and a PPARγ agonist which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. | 2014-03-27 |
20140088028 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds of formula (I) with substituents as specified in Claim | 2014-03-27 |
20140088029 | NOVEL PYRAZOLE DERIVATIVE - Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): | 2014-03-27 |
20140088030 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES - The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-α-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic, antimutagenic, antineoplastic, anti-thrombotic and vasodilatory formulations, or in any other field of application. | 2014-03-27 |
20140088031 | Triazole Compounds and Methods of Making and Using the Same - The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. | 2014-03-27 |
20140088032 | TREATMENT OF MASTITIS - The invention relates to a veterinary composition for intramammary administration comprising a combination of an antibacterial agent and a Toll-Like-Receptor (TLR) agonist and to the use of said composition for the treatment of mastitis in lactating ruminants. | 2014-03-27 |
20140088033 | NEW BORANOPHOSPHATE ANALOGUES OF CYCLIC NUCLEOTIDES - The present invention relates to novel boranophosphate analogues of cyclic nucleotides. The invention further relates to the use of such compounds as reagents for signal transduction research or as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and/or as hydrolysis- and oxidation-resistant ligands for affinity chromatography, for antibody production or for diagnostic applications e.g. on chip surfaces and/or as additive for organ transplantation storage solutions. | 2014-03-27 |
20140088034 | NITRIC OXIDE/cGMP PATHWAY INHIBITION OF VLA-4 RELATED CELL ADHESION - The invention provides methods of treating nitric oxide/cGMP pathway-cell adhesion disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention relates to a method for down-regulating α | 2014-03-27 |
20140088035 | TREATING SCHIZOPHRENIA - The specification provides methods of treating a subject suffering from a negative symptom of schizophrenia and methods of determining whether a subject is suffering from or at risk for developing a negative symptom of schizophrenia. | 2014-03-27 |
20140088036 | POLYPHOSPHATE AND PYROPHOSPHATE DERIVATIVE OF SACCHARIDES - The present invention provides, among other things, phosphorylated and pyrophosphate derivatives of mono-, di- and oligosaccharides, as well as structural derivatives of these compounds. These compounds have a variety of uses including for pharmaceutical applications. Also provided are methods of use in the treatment of disease, including diseases related to oxygen delivery. | 2014-03-27 |
20140088037 | Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate - The invention relates to a sterilized composition comprising at least one hyaluronic acid or biologically acceptable salt thereof, alone or in a mixture, and magnesium ascorbyl phosphate, in a ratio [HA]/[MAP] by mass of the amount of hyaluronic acid or salt thereof [HA] to the amount of magnesium ascorbyl phosphate [MAP] of greater than or equal to 1, the amount of magnesium ascorbyl phosphate being between 0.001% and 1% by weight, relative to the total weight of said composition, with an elastic component G′ which is retained or improved after sterilization and is between 5 and 400 Pa. It also relates to a composition of the invention which further includes dimethyl sulfone, to methods for producing same, and to uses thereof. | 2014-03-27 |
20140088038 | COMPOSITIONS AND METHODS FOR STABILIZED POLYSACCHARIDE FORMULATIONS - Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid (“HA”), in combination with at least one stabilizer. The composition can include a stabilizer that increases the stability and shelf-life of the HA. In another embodiment, the compositions and methods can also include an additional component, such as one or more glycosaminoglycans (“GAG”) or GAG precursors. Examples of GAGs or GAG precursors can include chondroitin sulfate (“CS”), dermatan sulfate, heparin, heparan sulfate, keratan sulfate, and glucosamine (“GlcN”). | 2014-03-27 |
20140088039 | OPHTHALMIC SOLUTION CONTAINING HYALURONIC ACID OR SALT THEREOF AND PROPYLENE GLYCOL - An aqueous ophthalmic solution containing hyaluronic acid or a salt thereof at a concentration from 0.03 to 0.5% (w/v) and propylene glycol at a concentration from 0.1 to 1.0% (w/v) comprises as a sole preservative, benzalkonium chloride at a concentration from 0.001 to 0.002% (w/v) and comprises an ionic tonicity agent at such a concentration that an osmotic pressure ratio of the ophthalmic solution becomes from 0.9 to 1.1. | 2014-03-27 |
20140088040 | COSMETIC SOLUTION, METHOD FOR PRODUCING COSMETIC SOLUTION, AND COSMETIC METHOD - Provided are a cosmetic solution and a method for producing the cosmetic solution, the cosmetic solution being easy to store and also easy to handle during use, and moreover having a high moisturizing function, without the use of a preservative. Hyaluronic acid/or a hyaluronic acid compound is dispersed in a polyvalent alcohol, also, an organic acid and/or organic acid salt different from the hyaluronic acid and/or hyaluronic acid compound is dispersed in a polyvalent alcohol such that it contains no water. The solution contains 0.01 to 2.0 wt % hyaluronic acid and/or hyaluronic acid compound 97 wt % or more polyvalent alcohol, is weakly acidic; i.e. 5≦pH<7 due to the organic acid and/or organic acid salt. | 2014-03-27 |
20140088041 | FUNGICIDAL PENFLUFEN MIXTURES - The invention relates to mixtures comprising penflufen, to the use of these mixtures for protecting industrial materials and to a method for treating industrial materials with the penflufen mixtures. | 2014-03-27 |
20140088042 | Proteasome Inhibitors And Methods Of Using The Same - The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity. | 2014-03-27 |
20140088043 | OMEGA-3 COMPOSITIONS - The present invention relates to compositions comprising omega-3 fatty acid derivatives, and in particular to compositions comprising omega-3 phospholipids in combination with other omega-3 derivatives. | 2014-03-27 |
20140088044 | PRODUCT COMPRISING A NICOTINE-CONTAINING MATERIAL AND AN ANTI-CANCER AGENT - The invention is directed to a product comprising a nicotine-containing material and an anti-cancer agent. The product is applicable in the treatment and/or prevention of cancer and precancerous conditions as well as for preventing cancer recurrence. | 2014-03-27 |
20140088045 | PRODUCT COMPRISING A NICOTINE-CONTAINING MATERIAL AND AN ANTI-CANCER AGENT - The present invention provides a composition comprising a nicotine-containing material and an anti-cancer agent usable in the treatment and/or prevention or reduction of the risk of cancer and precancerous conditions as well as for preventing or reducing the risk of cancer recurrence. Furthermore, a composition comprising a nicotine-containing material and an anti-inflammatory agent usable in the treatment and/or prevention or reduction of the risk of inflammation, is provided. The nicotine containing composition can also include both an anti-cancer agent and an anti-inflammatory agent A device for administering the composition of the present invention to subjects can be a cigarette, smoking pipe, smokeless tobacco, electronic cigarette, transdermal patch or the like. | 2014-03-27 |
20140088046 | PHENICOL ANTIBACTERIAL AGENTS - The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds. | 2014-03-27 |
20140088047 | USE OF LONG CHAIN POLYUNSATURATED FATTY ACID DERIVATIVES TO TREAT SICKLE CELL DISEASE - The present invention relates to the use of long chain polyunsaturated fatty acids to treat diseases associated with red blood cells and cell membranes, and in particular to the use of derivatives of long chain fatty acids to treat sickle cell disease. | 2014-03-27 |
20140088048 | DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES - A compound having the structure | 2014-03-27 |
20140088049 | METHOD AND APPARATUS FOR VITAMIN D ENHANCEMENT IN MUSHROOMS - An apparatus and method for increasing Vitamin D content in mushrooms is disclosed. A mushroom slurry of comminuted or pulverized mushrooms or mushroom parts and liquid, such as water, is passed under a UV light source and subjected to one or more pulses of UV light. The slurry may be conveyed to the UV light source by a vibrating conveyor. After UV light exposure, the treated slurry may be dried and ground into a powder, or the treated slurry may be filtered and the insoluble portion may be dried and ground into a powder. The irradiated mushroom powder has a mass fraction of Vitamin D2 of at least 2500 IU/gram of powder, and more preferably at least 20,000 IU/gram of powder. Irradiated mushroom powder may be incorporated into consumable food product for humans or animals, and/or may be incorporated into topical preparations for cosmetic use. | 2014-03-27 |
20140088050 | USE OF ANDROGEN FOR DISEASE TREATMENT - By lowering and then after raising the amount of SHBG in the body, an effective method for treatment of various diseases is achieved. First and seconds androgens, namely, anabolic steroids are used to both lower the SHBG and, thereafter raise the testosterone in the body until equilibrium between the SHBG and the second steroid, to normalize the FAI. Stanozolol is the preferred anabolic steroid used herein to lower the SHBG and testosterone is used to normalize the FAI. | 2014-03-27 |
20140088051 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES - Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | 2014-03-27 |
20140088052 | CHALCONE DERIVATIVES AS NRF2 ACTIVATORS - Compounds and methods for treating or preventing a disease, disorder or condition associated with an Nrf2-regulated pathway, including those associated with an autoimmune disease, comorbidity associated with diabetes, such as retinopathy and nephropathy, bone marrow transplant for leukemia and related cancers, bone marrow deficiencies, inborn errors of metabolism, and other immune disorders, oxidative stress, respiratory infection, ischemia, neurodegenerative disorders, radiation injury, neutropenia caused by chemotherapy, autoimmunity, and congenital neutropenic disorders, and for restoring a corticosteroid responsiveness, in a subject are provided. | 2014-03-27 |
20140088053 | INHIBITORS OF 17Beta-HSD1, 17Beta-HSD3 AND 17Beta-HSD10 - The present application discloses 17β hydroxy steroid dehydrogenase (17β HSD) type 1, 3, 10 inhibitors and use thereof (alone and in combination) in the treatment of cancer and other afflictions. 17β HSD1 inhibitors include estradiol derivatives with a nieta-carbamoylbenzyl substituent at C 16. 17β HSD3/HSD10 inhibitors include androsterone derivatives substituted at the C3 position with a sulfonamide piperazine. Also disclosed are compounds that are inhibitors of both 17β HSD1 and 17β HSD3 that have a spiro-morpholine substituent at C20. | 2014-03-27 |
20140088055 | COMPOSITIONS AND METHODS FOR INCREASING TELOMERASE ACTIVITY - The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and for enhancing proliferation of stem and progenitor cells. | 2014-03-27 |
20140088056 | CARDIAC GLYCOSIDES ARE POTENT INHIBITORS OF INTERFERON-BETA GENE EXPRESSION - The invention provides for a method of inhibiting interferon-beta gene expression and/or reducing the level of interferon-beta in a cell by contacting the cell with a Na | 2014-03-27 |
20140088057 | METHODS OF TREATING PRE-TERM LABOR - A method of treating pre-term labor in pregnant human patient expressing melatonin receptors in her myometrial cells comprises administering an inhibitor of MT2R, an inhibitor of protein kinase C, an inhibitor of phospholipase C, or a combination thereof to the patient. | 2014-03-27 |
20140088058 | SELECTIVE CNS DELIVERY OF MIFEPRISTONE (RU486) TO MODULATE THE TIMING OF THE SPONTANEOUS LH SURGE DURING FOLLICULAR STIMULATION CYCLES - The present invention relates to a new pharmaceutical product containing an antiprogestin molecule, such as mifepristone (RU486), administered by the nasal route and to be used to modulate the timing of the spontaneous LH surge as part of follicular stimulation cycles intended for Assisted Reproductive Technology (ART). In particular, it details the route of administration and the dosages that ensure effective delay of the LH surge without incurring in the antifolliculogenetic effects of the antiprogestinic. It also details the overall treatment method as resulting from the use of the new drug product. | 2014-03-27 |
20140088059 | Compositions and Methods for Localized Drug Delivery through Mammary Papillae - The invention provides compositions and methods for the prevention, diagnosis, or treatment of conditions affecting breast tissue. The compositions can include one or more therapeutic agents or diagnostic agents, and an effective carrier. The composition can be specifically adapted for transdermal permeation through the mammary papilla, areola, or a combination thereof, and into underlying breast tissue. | 2014-03-27 |
20140088060 | METHOD OF TREATING DISORDER RELATED TO HIGH CHOLESTERAL CONCENTRATION - A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): | 2014-03-27 |
20140088061 | PHARMACEUTICAL COMPOSITION - The invention relates to a solid pharmaceutical composition comprising solid amorphous fulvestrant, said composition being formulated in combination with a solubilizing composition. The invention also relates to a method for preparing said composition and a kit including the composition. | 2014-03-27 |
20140088062 | COMPOSITIONS COMPRISING FUSIDIC ACID AND PACKAGES THEREFOR - Described are solid pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, dosage units of the pharmaceutical compositions, and packages for pharmaceutical compositions of fusidic acid, and pharmaceutically acceptable salts thereof, which increase stability against the degradation of the fusidic acid, and pharmaceutically acceptable salts thereof. Also described are uses of the pharmaceutical compositions and dosage units in treating diseases. | 2014-03-27 |
20140088063 | AGENTS FOR TREATING NEURODEGENERATIVE DISORDERS - The present invention relates to compounds of formula (I) or (I′), use of these compounds to treat mental disorders, especially depressions of different etiology, and methods for their preparation. The compounds that are provided for the treatment of mental disorders can be presented by a general formula (I) as meso-form—S,2S,1′R,2′R-1-[ω-(3,3-dialkyldiaziridin-1-yl)alkyl]-3,3-dialkyldiaziridines: | 2014-03-27 |
20140088064 | PROCESS - The invention provides a method of forming an iron hydroxypyrone compound comprising reacting a hydroxypyrone with a non-carboxylate iron salt in an aqueous solution, and precipitating the iron hydroxypyrone compound from the aqueous solution having a pH of greater than 7. | 2014-03-27 |
20140088065 | COMPOSITION AND METHOD FOR AFFECTING OBESITY AND RELATED CONDITIONS - A composition including an effective amount of a compound including manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP), derivatives or analogs thereof to induce a reduction in body weight of a mammal or to improve insulin sensitivity of an obese mammal. A method including introducing an effective amount of a compound including manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP), derivatives or analogs thereof to a mammal to induce a reduction in body weight or to induce an increase in metabolism or insulin sensitivity of the mammal. | 2014-03-27 |
20140088066 | PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - The present disclosure relates to novel pharmaceutical compositions comprising a nanoparticle associated with, tether to, or encapsulating a platinum-based active pharmaceutical agent. The platinum-based drug is released from the nanoparticles in a controlled fashion. Also contemplated are methods of making the nanoparticles, as well as methods for using them in the treatment or prevention of diseases or conditions. One embodiment relates to phenanthriplatin nanoparticles and methods of using and making the same. | 2014-03-27 |
20140088067 | TAZOBACTAM ARGININE COMPOSITIONS - This disclosure provides compositions containing solid forms of tazobactam arginine, and methods of manufacturing and using these compositions. | 2014-03-27 |
20140088068 | 1,6-Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed. | 2014-03-27 |
20140088069 | NOVEL ANTIBACTERIAL COMBINATION THERAPY - An antibacterial composition is provided including a combination of a β-lactam antibiotic that has a binding affinity for bacterial penicillin-binding protein 2; and a non-antibiotic compound which may be a thienopyridine or a non-thienopyridine compound. A method of treatment using the composition is also provided. | 2014-03-27 |
20140088070 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed. | 2014-03-27 |
20140088071 | sGC STIMULATORS - Compounds of Formula (IA) and Formula (IB) are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. | 2014-03-27 |
20140088072 | EXTENDED RISK ASSESSMENT PANEL FOR INDIVIDUALIZED TREATMENT OF CARDIOVASCULAR DISEASE, AND METHODS RELATED THERETO - Disclosed is a personalized diagnostic and treatment solution for cardiovascular disease. The invention comprises an extended CVD risk assessment panel, combining tests for traditional and new important risk markers, and methods for devising a personalized treatment plan for a patient via the use of a CVD diagnosis and treatment protocol algorithm. The new important risk markers include HDL subpopulation profile by two-dimensional gel-electrophoresis, plasma sterols, direct measurement of sdLDL-C, determination of CRP molecular forms, glycated albumin as a percentile of total albumin, and other specialized testing pertaining to apolipoprotein E and Factor V Leiden genotyping, NT-proBNP and adiponectin. This solution provides a more complete risk assessment of an individual than merely measuring traditional CVD risk markers, and enables the healthcare practitioner to optimize therapy for patients with or without established CVD. This solution presents the advantages of greater accuracy, savings in time and cost over existing testing and treatment methods. | 2014-03-27 |
20140088073 | METHODS FOR DETERMINING WHETHER A PATIENT SHOULD BE ADMINISTERED A DRUG THAT INHIBITS CHOLESTEROL ABSORPTION - The invention generally relates to methods for determining whether a patient should be administered a drug that inhibits cholesterol absorption. In certain aspects, methods of the invention involve obtaining a sample from a patient, conducting an assay on the sample to obtain a level of a cholesterol absorption marker, and comparing the level to a reference level, in which a level above the reference level indicates that the patient should be administered a drug that inhibits cholesterol absorption. | 2014-03-27 |
20140088074 | FLUORINATED ARYLALKYLAMINOCARBOXAMIDE DERIVATIVES - Fluorinated arylalkylaminocarboxamide derivatives of formula (I) are described wherein W, J, n, R | 2014-03-27 |
20140088075 | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES - The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound. | 2014-03-27 |
20140088076 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF - The invention provides novel compounds having the general formula: | 2014-03-27 |
20140088077 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS - The invention relates to substituted tetrahydronaphthalenes and derivatives thereof, and also to the physiologically compatible salts and physiologically functional derivatives thereof, to preparation thereof, to medicaments comprising at least one inventive substituted tetrahydronaphthalene or derivative thereof, and to the use of the inventive substituted tetrahydronaphthalenes and derivatives thereof as medicaments. | 2014-03-27 |
20140088078 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same - The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 2014-03-27 |
20140088079 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS - The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound. | 2014-03-27 |
20140088080 | IMIDAZOPYRIDINE COMPOUNDS | 2014-03-27 |
20140088081 | Amino-Heterocyclic Compounds - The invention provides PDE9-inhibiting compounds of Formula (I), | 2014-03-27 |
20140088082 | INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS - Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, | 2014-03-27 |
20140088083 | USE OF MEMANTINE (NAMENDA) TO TREAT AUTISM, COMPULSIVITY, AND IMPULSIVITY - The present invention relates to the treatment of compulsive, impulsive and pervasive developmental disorders. More particularly, the methods described herein comprise administration of memantine to an individual suffering from such a disorder in an amount effective to relieve one or more symptoms of said disorder. In particularly preferred aspects, the invention is directed to the use of memantine for the treatment of autism | 2014-03-27 |
20140088084 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention relates to novel heterocyclic compounds of the formula | 2014-03-27 |
20140088085 | Substituted Benzoazepines As Toll-Like Receptor Modulators - Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease. | 2014-03-27 |
20140088086 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION - Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α | 2014-03-27 |
20140088087 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE - This disclosure relates to new azepino[4,5-b]indole compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new 1,2,3,4,5,6-tetrahydroazepino[4,5-b]indoles. Pharmaceutical compositions are also provided. | 2014-03-27 |
20140088088 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES - The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R | 2014-03-27 |
20140088089 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND METHODS OF PREPARATION - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds, such as those in formulas (V)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The present invention is further directed to methods of preparing a conjugate of a cell-binding agent and a cytotoxic compound. The methods comprise the use of an imine reactive compound to enable efficient conjugations of cytotoxic compounds with cell binding agents. | 2014-03-27 |
20140088090 | 6,7-DIHYDRO-[1,3,4]THIADIAZOLO-[3,2-a][1,3]DIAZEPIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS HYPNOTIC OR ANESTHETIC AGENT AND METHOD FOR THEIR PREPARATION - The present invention relates to a compound of formula 1, a pharmaceutical composition containing the compound, a method for its preparation as well as the use of the compound as hypnotic agent or anesthetic agent. | 2014-03-27 |
20140088091 | 6,7-DIHYDRO-[1,3,4]THIADIAZOLO-[3,2-a][1,3]DIAZEPIN DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS NEUROMUSCULAR BLOCKER OR SKELETAL MUSCLE RELAXANT, AND METHOD FOR THE PREPARATION - The present invention relates to a compound of formula 1, a pharmaceutical composition containing the compound, a method for its preparation as well as the use of the compound as neuromuscular blocker or skeletal muscle relaxant. | 2014-03-27 |
20140088092 | COMBINATION AND METHODS FOR CONTROLLING TURFGRASS PESTS - The present invention relates to the use of active substance combinations for controlling animal pests, for example, from the chinch bug family (Lygaeidae), as well as animal pests that has shown resistance to pyrethroids. | 2014-03-27 |
20140088093 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS - Described herein are antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition. | 2014-03-27 |
20140088094 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE - The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting RORγ activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided. | 2014-03-27 |
20140088095 | METHOD FOR TREATING PAIN, ANXIETY OR DEPRESSION USING CARBAMOYLOXY ALKANOYL PIPERAZINE COMPOUND - There is provided a novel carbamoyloxy arylalkanoyl arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the Formula 1, and pharmaceutically available salts or hydrates thereof. Also, there are provided a pharmaceutical composition for treating pain, anxiety or depression including an effective amount of the compound, and a method for treating pain, anxiety or depression in mammals by administering an effective amount of the compound to the mammals in need of treatment thereof. | 2014-03-27 |
20140088096 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME - Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: | 2014-03-27 |
20140088097 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF - The present invention relates to compounds of general formula (I) | 2014-03-27 |
20140088098 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 2014-03-27 |
20140088099 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION - Chemical compounds that modulate kinase activity, including PI3 kinase activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. | 2014-03-27 |
20140088100 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR - Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases. | 2014-03-27 |
20140088101 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE - The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). | 2014-03-27 |
20140088102 | (ALPHA-SUBSTITUTED CYCLOALKYLAMINO AND HETEROCYCLYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES - Provided herein are (alpha-substituted cycloalkylamino or heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases. | 2014-03-27 |
20140088103 | (FUSED RING ARYLAMINO AND HETEROCYCLYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES - Provided herein are (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula (I), and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases. | 2014-03-27 |
20140088104 | NOVEL SMALL-MOLECULES AS THERAPEUTICS - The present invention provides compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression. | 2014-03-27 |
20140088105 | Cyclohexyl Amide Derivatives and Their Use as CRF-1 Receptor Antagonists - There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF | 2014-03-27 |
20140088106 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2014-03-27 |
20140088107 | OPHTHALMIC PREPARATION COMPRISING A PGF2ALPHA ANALOGUE - The present invention relates to an aqueous ophthalmic preparation comprising a PGF2α analogue and at least one polyvinyl alcohol and the use thereof for the treatment of glaucoma and ocular hypertension. | 2014-03-27 |
20140088108 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS - Novel compounds selected from 2-(3-aminoaryl) amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors. | 2014-03-27 |
20140088109 | N-((1R,2S,5R)-5-(TERT-BUTYLAMINO)-2-((S)-3-(7-TERT-BUTYLPYRAZOLO[1,5-A][1,- 3,5]TRIAZIN-4-YLAMINO)-2-OXOPYRROLIDIN-1-YL)CYCLOHEXYL)ACETAMIDE, A DUAL MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESSES - The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin -1-yl)cyclohexyl)acetamide: | 2014-03-27 |
20140088110 | FUSED BICYCLIC IMIDAZOLES - Compounds of formula (I) | 2014-03-27 |
20140088111 | Novel Bicyclic Pyridinones - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I | 2014-03-27 |
20140088112 | ALKYNE BENZOTRIAZOLE DERIVATIVES - The present invention is directed to alkyne benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. | 2014-03-27 |
20140088113 | METHODS AND KITS THAT IDENTIFY TUMORS RESPONSIVE TO SRC INHIBITORS - Disclosed herein are methods of predicting whether or not a subject will benefit from treatment with a Src inhibitor on the basis of the expression of one or more of Von Hippel Lindau (VHL), Src, PTP1B, pFAK, HIF-1α, and/or CA-IX in a tumor sample from the subject. | 2014-03-27 |
20140088114 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention. | 2014-03-27 |
20140088115 | PHARMACEUTICAL COMPOSITIONS HAVING IMPROVED STORAGE STABILITY - The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent | 2014-03-27 |